Albiglutide

a unique GLP-1 receptor agonist

Marc S. Rendell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure. As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1%, less than several competitor GLP-1 RAs. The benefit on weight reduction is minimal compared to other GLP-1 RAs. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its lower level of GI intolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

Original languageEnglish (US)
Pages (from-to)1557-1569
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Glucagon-Like Peptide 1
Pharmacodynamics
Drug Approval
Injections
Pharmacokinetics
Expert Testimony
European Union
Medical problems
Hypoglycemic Agents
PubMed
Pancreatitis
Renal Insufficiency
Weight Loss
Therapeutics
Food
Glucagon-Like Peptide-1 Receptor
rGLP-1 protein

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Albiglutide : a unique GLP-1 receptor agonist. / Rendell, Marc S.

In: Expert Opinion on Biological Therapy, Vol. 16, No. 12, 01.12.2016, p. 1557-1569.

Research output: Contribution to journalArticle

Rendell, Marc S. / Albiglutide : a unique GLP-1 receptor agonist. In: Expert Opinion on Biological Therapy. 2016 ; Vol. 16, No. 12. pp. 1557-1569.
@article{ff7a36d5953b48d6ad5aef8f58ec7216,
title = "Albiglutide: a unique GLP-1 receptor agonist",
abstract = "Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure. As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1{\%}, less than several competitor GLP-1 RAs. The benefit on weight reduction is minimal compared to other GLP-1 RAs. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2{\%} of participants. A large long term study now underway will determine if albiglutide, with its lower level of GI intolerance, has a place in the treatment of patients with increased risk of cardiovascular events.",
author = "Rendell, {Marc S.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1080/14712598.2016.1240780",
language = "English (US)",
volume = "16",
pages = "1557--1569",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Albiglutide

T2 - a unique GLP-1 receptor agonist

AU - Rendell, Marc S.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure. As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1%, less than several competitor GLP-1 RAs. The benefit on weight reduction is minimal compared to other GLP-1 RAs. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its lower level of GI intolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

AB - Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure. As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1%, less than several competitor GLP-1 RAs. The benefit on weight reduction is minimal compared to other GLP-1 RAs. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its lower level of GI intolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=84990236864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990236864&partnerID=8YFLogxK

U2 - 10.1080/14712598.2016.1240780

DO - 10.1080/14712598.2016.1240780

M3 - Article

VL - 16

SP - 1557

EP - 1569

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -